FIC20220032I1 - Pneumokokkipolysakkaridi serotyyppi 33F konjugoituna CRM197-kantajaproteiiniin (2-((2-oksoetyyli)tio)etyyli) karbamaatti (eTEC)-välikeosan kautta - Google Patents
Pneumokokkipolysakkaridi serotyyppi 33F konjugoituna CRM197-kantajaproteiiniin (2-((2-oksoetyyli)tio)etyyli) karbamaatti (eTEC)-välikeosan kauttaInfo
- Publication number
- FIC20220032I1 FIC20220032I1 FIC20220032C FIC20220032C FIC20220032I1 FI C20220032 I1 FIC20220032 I1 FI C20220032I1 FI C20220032 C FIC20220032 C FI C20220032C FI C20220032 C FIC20220032 C FI C20220032C FI C20220032 I1 FIC20220032 I1 FI C20220032I1
- Authority
- FI
- Finland
- Prior art keywords
- etec
- oxoethyl
- carbamate
- thio
- conjugated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684043P | 2012-08-16 | 2012-08-16 | |
| PCT/IB2013/056597 WO2014027302A1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FIC20220032I1 true FIC20220032I1 (fi) | 2022-08-05 |
Family
ID=49385307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIC20220032C FIC20220032I1 (fi) | 2012-08-16 | 2022-08-05 | Pneumokokkipolysakkaridi serotyyppi 33F konjugoituna CRM197-kantajaproteiiniin (2-((2-oksoetyyli)tio)etyyli) karbamaatti (eTEC)-välikeosan kautta |
Country Status (32)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3421051B1 (en) | 2012-08-16 | 2020-05-13 | Pfizer Inc | Glycoconjugation processes and compositions |
| HRP20211288T1 (hr) * | 2014-01-21 | 2021-11-26 | Pfizer Inc. | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati |
| EP3096785B1 (en) | 2014-01-21 | 2020-09-09 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PT3096783T (pt) * | 2014-01-21 | 2021-08-16 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
| EP3443983B1 (en) | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
| RU2760005C2 (ru) | 2014-03-13 | 2021-11-22 | Университет Базель | УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА |
| CN107427568B (zh) | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
| RU2692923C2 (ru) * | 2015-05-04 | 2019-06-28 | Пфайзер Инк. | Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения |
| CA2988366C (en) * | 2015-06-08 | 2021-12-07 | Serum Institute Of India Private Ltd. | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof. |
| IL303998A (en) | 2015-07-21 | 2023-08-01 | Pfizer | Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses |
| AU2016323377B2 (en) | 2015-09-16 | 2021-04-15 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
| CA3031799A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| MY199342A (en) | 2016-08-05 | 2023-10-24 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| RS65362B1 (sr) | 2016-09-02 | 2024-04-30 | Sanofi Pasteur Inc | Vakcina protiv neisseria meningitidis |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| MX2019007910A (es) | 2016-12-30 | 2019-12-05 | Sutrovax Inc | Conjugados de polipeptido-antigeno con aminoacidos no naturales. |
| WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| MX2019014829A (es) * | 2017-06-10 | 2020-08-17 | Inventprise Llc | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| AU2018328040B2 (en) * | 2017-09-07 | 2025-01-16 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| US11491216B2 (en) | 2017-09-07 | 2022-11-08 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| KR102812816B1 (ko) | 2018-02-05 | 2025-05-27 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| JP6950099B2 (ja) | 2018-02-05 | 2021-10-13 | サノフィ パスツール インコーポレイティッド | 多価肺炎球菌多糖体−タンパク質複合体組成物 |
| KR20200141053A (ko) * | 2018-03-23 | 2020-12-17 | 코라넥스 캐피탈 | 치료 도구로서의 정밀 당 접합체 |
| BR112020021296A2 (pt) | 2018-04-18 | 2021-01-26 | Sk Bioscience Co., Ltd. | polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
| MX2022005252A (es) | 2019-11-01 | 2022-06-08 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| JP2021132644A (ja) | 2020-02-21 | 2021-09-13 | ファイザー・インク | 糖の精製 |
| IL295632A (en) | 2020-02-23 | 2022-10-01 | Pfizer | Escherichia coli preparations and their methods |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| BR112023004819A2 (pt) | 2020-09-17 | 2023-04-18 | Janssen Pharmaceuticals Inc | Composições de vacinas multivalentes e seus usos |
| WO2022084852A1 (en) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| EP4237428A2 (en) | 2020-10-27 | 2023-09-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US20240000912A1 (en) | 2020-11-04 | 2024-01-04 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| CA3221074A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP2024521847A (ja) | 2021-05-28 | 2024-06-04 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用 |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| PE20251701A1 (es) | 2022-11-22 | 2025-07-02 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos |
| KR20250113501A (ko) | 2022-12-01 | 2025-07-25 | 화이자 인코포레이티드 | 폐렴구균 접합체 백신 제형 |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| WO1993013302A1 (de) | 1991-12-23 | 1993-07-08 | Michael Zoche | Motor mit einer vorrichtung zur entölung |
| EP0616034B1 (en) | 1993-03-05 | 2004-10-20 | Wyeth Holdings Corporation | Plasmid for production of CRM protein and diphtheria toxin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| WO1998056942A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| MXPA01003228A (es) | 1998-09-30 | 2003-06-24 | American Cyanamid Co | Holotoxina de colera mutante como un coadyuvante. |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| YU66103A (sh) * | 2001-01-23 | 2006-05-25 | Aventis Pasteur | Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina |
| DE60234695D1 (de) | 2001-06-07 | 2010-01-21 | Univ Colorado | Mutantenformen von cholera holotoxin als adjuvans |
| AU2002322380B2 (en) | 2001-06-07 | 2006-11-02 | Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences | Mutant forms of cholera holotoxin as an adjuvant |
| CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
| WO2004031394A2 (en) * | 2002-10-03 | 2004-04-15 | Wyeth Holdings Corporation | Process for preparing monoprotected diols from symmetric diols |
| JP5102487B2 (ja) * | 2003-03-07 | 2012-12-19 | ワイス・ホールディングズ・コーポレイション | 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体 |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| JP2007532655A (ja) * | 2004-04-14 | 2007-11-15 | ワイス | ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン４２−エステルおよびジカルボン酸とのｆｋ−５０６３２−エステルの調製プロセス |
| US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
| EP2425856A1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| DK2384765T3 (en) * | 2005-12-22 | 2017-01-09 | Glaxosmithkline Biologicals Sa | Vaccine against Streptococcus pneumoniae. |
| TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
| US7605257B2 (en) * | 2006-03-07 | 2009-10-20 | Wyeth | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| US20070253985A1 (en) | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
| WO2008157590A1 (en) | 2007-06-20 | 2008-12-24 | Baxter International Inc. | Modified polysaccharides for conjugate vaccines |
| RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
| WO2011041003A2 (en) | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| JP5837486B2 (ja) * | 2009-07-03 | 2015-12-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | カチオン非依存性マンノース６−リン酸受容体を標的とする化合物 |
| PL2503995T3 (pl) * | 2009-11-24 | 2018-01-31 | Grifols Therapeutics Inc | Sposoby liofilizacji, kompozycje i zestawy |
| RU2013131795A (ru) * | 2010-12-10 | 2015-01-20 | Мерк Шарп Энд Домэ Корп. | Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций |
| MX358840B (es) * | 2011-09-07 | 2018-09-05 | Prolynx Llc | Hidrogeles con reticulación biodegradable. |
| EP3421051B1 (en) | 2012-08-16 | 2020-05-13 | Pfizer Inc | Glycoconjugation processes and compositions |
| EP3096785B1 (en) | 2014-01-21 | 2020-09-09 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3443983B1 (en) | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
-
2013
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en not_active Ceased
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active Active
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es active IP Right Grant
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243B1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-22 LU LU00273C patent/LUC00273I2/fr unknown
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
- 2022-08-04 NO NO2022034C patent/NO2022034I1/no unknown
- 2022-08-05 FI FIC20220032C patent/FIC20220032I1/fi unknown
-
2023
- 2023-06-21 US US18/338,961 patent/US12447203B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20220032I1 (fi) | Pneumokokkipolysakkaridi serotyyppi 33F konjugoituna CRM197-kantajaproteiiniin (2-((2-oksoetyyli)tio)etyyli) karbamaatti (eTEC)-välikeosan kautta | |
| BR302012004398S1 (pt) | "configuração aplicada em dispositivo médico" | |
| BR302012005319S1 (pt) | Configuração aplicada a dispositivo de infusão | |
| BR302012005318S1 (pt) | Configuração aplicada a dispositivo de infusão | |
| BR302012005321S1 (pt) | Configuração aplicada a dispositivo de infusão | |
| EP2880153A4 (en) | PREPARATION OF FMDV RESISTANT CATTLE BY ALLELSUBSTITUTION | |
| HUE050970T2 (hu) | Fagyasztva szárított hatóanyag-nanoszuszpenziók | |
| PT2854840T (pt) | Neurotoxina botulínica geneticamente modificada | |
| HUE062102T2 (hu) | Individualizált vakcinák a rák ellen | |
| CO6910189A2 (es) | Derivado heterociclico y farmacéutico | |
| IT1397845B1 (it) | Pinza pneumatica ad aghi | |
| BR302012006307S1 (pt) | Configuração aplicada em dispositivo médico | |
| BR302012006665S1 (pt) | Configuração aplicada a pneumático | |
| EP2709645A4 (en) | ENHANCED PEPTIDE PHARMACEUTICAL AGENTS | |
| DK2734499T3 (da) | Merocyanine derivatives | |
| SI3003386T1 (sl) | Konjugati zdravila s protitelesci | |
| IL230838A0 (en) | Pharmaceutical compositions | |
| PL2872497T3 (pl) | Pochodne chromanylowe do leczenia choroby mitochondrialnej | |
| BR302012004208S1 (pt) | Configuracao aplicada a capsula | |
| EP2862860A4 (en) | HETERO-AROMATIC DERIVATIVE FROM METHYL AND A CYCLIC AMINE | |
| BR112014009887A2 (pt) | vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue | |
| EP2917403A4 (en) | MIXED DRYING OF NANOFIBRILLATED POLYSACCHARIDE | |
| DK2875016T3 (da) | Carbamat-/urinstofderivater | |
| FR2994384B1 (fr) | Article cosmetique a appliquer sur les matieres keratiniques humaines. | |
| FR3000545B1 (fr) | Microbarometre a soufflet et a transducteur interferometrique |